Arrowhead Pharmaceuticals, Inc. (ARWR)
NASDAQ: ARWR · Real-Time Price · USD
82.58
+0.19 (0.23%)
Sep 1, 2026, 1:22 PM EDT - Market open
Arrowhead Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is October - September.
Millions USD. Fiscal year is Oct - Sep.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
| 669.5 | 829.45 | 3.55 | 240.74 | 243.23 | 138.29 | |
Revenue Growth | 16.84% | 23258.15% | -98.52% | -1.03% | 75.89% | 57.16% |
Gross Profit | 669.5 | 829.45 | 3.55 | 240.74 | 243.23 | 138.29 |
Selling, General & Admin | 188.9 | 138.5 | 113.44 | 104.08 | 132.44 | 85.44 |
Research & Development | 707.04 | 592.6 | 491.19 | 341.66 | 289.3 | 201.88 |
Operating Expenses | 895.93 | 731.1 | 604.63 | 445.74 | 421.74 | 287.32 |
Operating Income | -226.44 | 98.35 | -601.08 | -205 | -178.51 | -149.04 |
Interest Expense | -92.61 | -89.36 | -32.35 | -18.33 | - | - |
Interest & Investment Income | 52.55 | 37.29 | 22.72 | 15.3 | 5.03 | 6.12 |
Other Non Operating Income (Expenses) | 4.6 | 5.26 | -1.75 | 1.54 | 0.77 | 2.07 |
EBT Excluding Unusual Items | -271.08 | 51.53 | -612.46 | -206.49 | -172.71 | -140.85 |
Gain (Loss) on Sale of Assets | 19 | - | - | - | - | - |
Pretax Income | -252.08 | 51.53 | -612.46 | -206.49 | -172.71 | -140.85 |
Income Tax Expense | 20.05 | 21.42 | -2.77 | 2.78 | 3.79 | 0 |
Earnings From Continuing Operations | -272.13 | 30.11 | -609.69 | -209.28 | -176.49 | -140.85 |
Minority Interest in Earnings | -47.83 | -31.75 | 10.2 | 4 | 0.43 | - |
Net Income | -319.96 | -1.63 | -599.49 | -205.28 | -176.06 | -140.85 |
Net Income to Common | -319.96 | -1.63 | -599.49 | -205.28 | -176.06 | -140.85 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 140 | 134 | 120 | 107 | 105 | 104 |
Shares Outstanding (Diluted) | 140 | 134 | 120 | 107 | 105 | 104 |
Shares Change | 7.74% | 11.67% | 12.21% | 1.26% | 1.62% | 3.00% |
EPS (Basic) | -2.28 | -0.01 | -5.00 | -1.92 | -1.67 | -1.36 |
EPS (Diluted) | -2.28 | -0.01 | -5.00 | -1.92 | -1.67 | -1.36 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Free Cash Flow | -75.11 | 156.89 | -604.32 | -330.63 | -188.91 | 147.75 |
Free Cash Flow Per Share | -0.54 | 1.17 | -5.04 | -3.10 | -1.79 | 1.42 |
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
Operating Margin | -33.82% | 11.86% | -16927.06% | -85.16% | -73.39% | -107.77% |
Profit Margin | -47.79% | -0.20% | -16882.37% | -85.27% | -72.39% | -101.85% |
Free Cash Flow Margin | -11.22% | 18.92% | -17018.31% | -137.34% | -77.67% | 106.84% |
EBITDA | -200.64 | 122.27 | -582.49 | -192.51 | -168.09 | -140.77 |
EBITDA Margin | -29.97% | 14.74% | - | -79.97% | -69.11% | -101.79% |
D&A For EBITDA | 25.8 | 23.93 | 18.6 | 12.49 | 10.42 | 8.27 |
EBIT | -226.44 | 98.35 | -601.08 | -205 | -178.51 | -149.04 |
EBIT Margin | -33.82% | 11.86% | - | -85.16% | -73.39% | -107.77% |
Effective Tax Rate | - | 41.56% | - | - | - | - |